Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor in adult NASH
NCT03008070Phase 2Completed
- Sponsor
- Inventiva
- Start
- Feb 2017
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of lanifibranor in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Inventiva. Primary endpoint: SAF Activity Score Decrease of at Least 2 Points With no Worsening of the CRN Fibrosis Score at 24 weeks. Started Feb 2017; status: completed.
02
Drugs
lanifibranor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03008070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008070.